Johnson & Johnson (NYSE:JNJ) ~ Can Vertex Survive Post-Incivek?

Johnson & Johnson (NYSE:JNJ) [at Motley Fool] – Gilead Sciences and Johnson & Johnson are about to launch new oral hepatitis C treatments that will significantly reduce Vertex sales from Incivek. The company hopes drugs treating cystic fibrosis can …
Read more on this.

Johnson & Johnson (JNJ), with a current value of $261.58B, began trading this morning at $93.46.
Today’s price range has been between $92.53 and $93.49 per share with the price of the stock fluctuating between $68.51 to $94.42 over the last 52 weeks.
Johnson & Johnson (JNJ) shares are currently priced at 16.93x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 12.32x earnings multiple for the same period.
And for passive income investors, the company pays shareholders $2.64 per share annually in dividends, yielding 2.80%.
According to a consensus of 17 analysts, the earnings estimate of $1.20 per share would be $0.01 better than the year-ago quarter and a $0.02 sequential decrease. The full-year EPS estimate is $5.48 which would be a $0.38 improvement than last year’s full-year earnings.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $17.94 Billion. If realized, that would be a 2.16% increase over the year-ago quarter.
Recently, Deutsche Bank downgraded JNJ from Buy to Hold (Jul 17, 2013). Previously, Deutsche Bank upgraded JNJ from Hold to Buy.
The average price target for JNJ shares by the analysts covering the stock is $95.38, which is 2.05% above where the stock opened this morning.

Johnson & Johnson (NYSE:JNJ), together with its subsidiaries, engages in the research and development, manufacture and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .

Share the News | facebooktwittergoogle_plusredditlinkedin |

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

This post is over 2 years old. Sometimes images and links no longer work since they are from other sites. We have no control over these sites and we are sorry for this if it makes harder to understand the article.

Related Articles

Click for a Random Article: [This Month] | [This Year] | [All Time]

Comments are closed.